A1 Refereed original research article in a scientific journal

Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence




AuthorsVu, Hani; Sun, Yuliangzi; Xiong, Zherui; Tan, Xiao; Radford-Smith, Daniel; Causer, Andrew; Dickens, Alex M.; Hyötyläinen, Tuulia; Evstafev, Ilia; Oresic, Matej; Nefzger, Christian; O’Sullivan, Eoin D.; Watt, Matthew J.; Ramm, Grant A.; Clouston, Andrew; Irvine, Katharine M.; Nguyen, Quan H.; Powell, Elizabeth E.

PublisherElsevier

Publication year2026

Journal: JHEP Reports

Article number101657

Volume8

Issue2

eISSN2589-5559

DOIhttps://doi.org/10.1016/j.jhepr.2025.101657

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Open Access publication channel

Web address https://www.sciencedirect.com/science/article/pii/S2589555925003398?via%3Dihub

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/508577208

Self-archived copy's licenceCC BY NC ND

Self-archived copy's versionPublisher`s PDF


Abstract
Background & Aims

Granular detail about the location and nature of liver cell interactions and the metabolic, inflammatory and fibrogenic pathways driving progressive fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is needed to identify novel therapeutic targets.

Methods

We generated Visium spatial transcriptomic data from 33 human liver biopsies across the spectrum of MASLD. Gene expression data were overlaid with histological annotations to integrate spatial molecular and histopathological information, enabling interrogation of disease progression. Differential gene expression, pathway, cellular deconvolution and ligand-receptor interaction analyses were conducted for each annotated anatomical category, with specific protein expression validated using immunohistochemistry staining.

Results

Unsupervised clustering based on gene expression data classified the annotated spots into two main clusters enriched for fibro-inflammatory vs. parenchymal regions. Transcriptomic cellular deconvolution aligned well with manually annotated histopathological features. Fibrotic regions were enriched for genes involved in extracellular matrix/receptor interactions and inflammatory pathways (Benjamini-Hochberg adjusted p values <0.05), underscoring known pathological mechanisms. We also identified immunoglobulin gene induction in late-stage fibrosis, which was spatially associated with a senescence signature, as has previously been reported in aging tissues. Dynamic changes in metabolic gene expression from early to late fibrosis were observed, suggesting MASLD progression is accompanied by a decline in normal liver metabolic function and reprogramming of metabolic fuel utilisation from oxidative to glycolytic metabolism, which may be both a cause and a consequence of senescence.

Conclusions

Taken together, our valuable discovery dataset highlights the complex crosstalk between metabolic perturbations and inflammation underpinning fibrosis progression in MASLD.

Impact and implications

Metabolic dysfunction-associated steatotic liver disease (MASLD) has a complex pathogenesis driven by cell and matrix interactions in inflammatory niches. In this study, we identify a senescence signature in fibroinflammatory regions, characterised by high immunoglobulin expression and associated with a shift from oxidative to glycolytic metabolism. We identify spatially co-expressed ligand-receptor pairs, including senescence-associated factors, correlated with progressive fibrosis. This discovery dataset highlights the complex crosstalk between metabolic perturbations and inflammation underpinning fibrosis progression in MASLD and lays the groundwork for future research into the role of senescence in MASLD.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
EEP was supported by a QLD Health Targeted Clinical Research Fellowship. KMI is grateful for core laboratory funding from the Mater Foundation. QHN is supported by the NHMRC Investigator Grant (GNT2008928), the QIMRB National Centre for Spatial Tissue and AI Research (NCSTAR), and the ACRF Centre for Optimised Cancer Therapy (COCT).


Last updated on 11/03/2026 11:18:54 AM